United Kingdom NET Patient Survey Quality of Life Results Abstract #1062

Introduction: QoL is of paramount importance in patients diagnosed with cancer, this is especially true in patients with NETs since the median survival from diagnosis is 7 years.
Aim(s): This survey was conducted to assess the impact of NETs on the QoL of patients.
Materials and methods: INCA in conjunction with Novartis has performed the first global survey of patients with NETs. Hall & Partners fielded and analysed the results. The UK data reported in this abstract forms part of a much larger global survey which recruited >1900 patients. The UK data reported is based on 156 patients; average age = 57, 83% from England.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Raj Srirajaskanthan
Keywords: Quality of life, NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results
Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: RN Gladys Grance
#1217 The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Despite a rising incidence of NETs, few studies document the NET pt experience. We present data on quality of life (QoL) and the global NET pt perspective.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: Dr John Leyden
Keywords: Quality of life
#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg
#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors
Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Jonathan Strosberg
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, ...
#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye